116 related articles for article (PubMed ID: 20122728)
1. Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone.
Du J; Yuan Z; Zhang C; Fu W; Jiang H; Chen B; Hou J
Leuk Res; 2010 Nov; 34(11):1453-8. PubMed ID: 20122728
[TBL] [Abstract][Full Text] [Related]
2. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with thalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not undergoing upfront autologous stem cell transplantation: a phase II trial.
Dingli D; Rajkumar SV; Nowakowski GS; Gertz MA; Dispenzieri A; Lacy MQ; Hayman S; Fonseca R; Lust JA; Kyle RA; Greipp PR; Witzig TE
Haematologica; 2005 Dec; 90(12):1650-4. PubMed ID: 16330438
[TBL] [Abstract][Full Text] [Related]
4. [Effect of TNF-alpha gene polymorphism on outcome of thalidomide-based regimens for multiple myeloma].
DU J; Yuan ZG; Zhang CY; Fu WJ; Jiang H; Chen BA; Hou J
Zhonghua Xue Ye Xue Za Zhi; 2009 Oct; 30(10):649-53. PubMed ID: 19954656
[TBL] [Abstract][Full Text] [Related]
5. Association of TNF-alpha polymorphism with susceptibility to and severity of non-small cell lung cancer.
Shih CM; Lee YL; Chiou HL; Chen W; Chang GC; Chou MC; Lin LY
Lung Cancer; 2006 Apr; 52(1):15-20. PubMed ID: 16476505
[TBL] [Abstract][Full Text] [Related]
6. Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant.
Palumbo A; Falco P; Ambrosini MT; Petrucci MT; Musto P; Caravita T; Pregno P; Bertola A; Cavallo F; Ciccone G; Boccadoro M
Eur J Haematol; 2005 Nov; 75(5):391-5. PubMed ID: 16191088
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.
Dmoszynska A; Walter-Croneck A; Hus I; Grzasko N; Manko J; Jedrzejczak WW; Charlinski G; Usnarska-Zubkiewicz L; Skotnicki A; Wolska-Smolen T; Piszcz J; Kloczko J
Leuk Res; 2010 Oct; 34(10):1330-5. PubMed ID: 20627385
[TBL] [Abstract][Full Text] [Related]
8. Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib.
Vangsted AJ; Klausen TW; Abildgaard N; Andersen NF; Gimsing P; Gregersen H; Nexø BA; Vogel U
Ann Hematol; 2011 Oct; 90(10):1173-81. PubMed ID: 21347685
[TBL] [Abstract][Full Text] [Related]
9. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group.
Rajkumar SV; Blood E; Vesole D; Fonseca R; Greipp PR;
J Clin Oncol; 2006 Jan; 24(3):431-6. PubMed ID: 16365178
[TBL] [Abstract][Full Text] [Related]
10. Thalidomide-dexamethasone versus interferon-alpha-dexamethasone as maintenance treatment after ThaDD induction for multiple myeloma: a prospective, multicentre, randomised study.
Offidani M; Corvatta L; Polloni C; Piersantelli MN; Gentili S; Galieni P; Visani G; Alesiani F; Catarini M; Brunori M; Samori A; Burattini M; Centurioni R; Ferranti M; Giuliodori L; Candela M; Mele A; Marconi M; Leoni P
Br J Haematol; 2009 Mar; 144(5):653-9. PubMed ID: 19036082
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of thalidomide combined dexamethasone on newly diagnosed multiple myeloma].
Yuan ZG; Hou J; Wang DX; Fu WJ; Chen YB; Xi H
Ai Zheng; 2007 Dec; 26(12):1369-72. PubMed ID: 18076804
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms within the tumor necrosis factor-alpha promoter region in patients with HLA-B27-associated uveitis: association with susceptibility and clinical manifestations.
El-Shabrawi Y; Wegscheider BJ; Weger M; Renner W; Posch U; Ulrich S; Ardjomand N; Hermann J
Ophthalmology; 2006 Apr; 113(4):695-700. PubMed ID: 16581430
[TBL] [Abstract][Full Text] [Related]
13. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
14. Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma.
Wang M; Weber DM; Delasalle K; Alexanian R
Am J Hematol; 2005 Jul; 79(3):194-7. PubMed ID: 15981221
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.
Kaufman JL; Nooka A; Vrana M; Gleason C; Heffner LT; Lonial S
Cancer; 2010 Jul; 116(13):3143-51. PubMed ID: 20564642
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK; Sohn SK; Lee JH; Yang DH; Moon JH; Ahn JS; Kim HJ; Lee JJ;
Ann Hematol; 2010 May; 89(5):475-82. PubMed ID: 19921192
[TBL] [Abstract][Full Text] [Related]
17. [Molecular genetic analysis of the interleukin 6 and tumor necrosis factor alpha gene polymorphisms in multiple myeloma].
Iakupova EV; Grinchuk OV; Kalimullina DKh; Bakirov BA; Galimova RR; Makarova OV; Khusnutdinova EK; Viktorova TV
Mol Biol (Mosk); 2003; 37(3):420-4. PubMed ID: 12815949
[TBL] [Abstract][Full Text] [Related]
18. Survival and outcome of blastoid variant myeloma following treatment with the novel thalidomide containing regime DT-PACE.
Srikanth M; Davies FE; Wu P; Jenner MW; Ethell ME; Potter MN; Shaw BE; Saso RM; Dines S; Morgan GJ
Eur J Haematol; 2008 Dec; 81(6):432-6. PubMed ID: 18691254
[TBL] [Abstract][Full Text] [Related]
19. Thalidomide plus monthly high-dose dexamethasone in chemorefractory myeloma. Results of a phase II clinical study.
Bernardeschi P; Giustarini G; Montenora I; Turrisi G; Dentico P; Rossi S; Turano E; Fiorentini G
In Vivo; 2006; 20(6A):719-20. PubMed ID: 17203753
[TBL] [Abstract][Full Text] [Related]
20. [Factors affecting the response of thalidomide therapy for patients with multiple myeloma].
Agata M; Sameshima Y; Oda T; Kondo T; Ishiyama M; Yasunami T; Kazama H; Okamura T; Yoshinaga K; Shiseki M; Mori N; Yamada O; Sagawa K; Teramura M; Motoji T
Rinsho Ketsueki; 2010 Mar; 51(3):189-95. PubMed ID: 20379113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
